Journal
LIPIDS
Volume 47, Issue 9, Pages 927-930Publisher
SPRINGER HEIDELBERG
DOI: 10.1007/s11745-012-3691-0
Keywords
Autotaxin; Clinical laboratory testing; Immunoenzymetric assay; Lysophosphatidic acids; Ovarian cancer; Tumor marker
Funding
- Ministry of Education, Culture, Sports, Science and Technology, Japan
- Japanese Society of Laboratory Medicine Fund for the Promotion of Scientific Research
- Grants-in-Aid for Scientific Research [22249017] Funding Source: KAKEN
Ask authors/readers for more resources
Autotaxin (ATX) is a glycoprotein that was first identified in the conditioned medium of human melanoma cells as an autocrine motility factor. It possesses lysophospholipase D activity, producing the bioactive lipid mediator lysophosphatidic acid (LPA) from lysophosphatidylcholine. Enhanced expression of ATX mRNA has been reported in various cancer cells and tissues, and it has been speculated that ATX overexpression in cancer cells may be associated with aberrant LPA production. LPA and ATX have been implicated in cancer progression and metastasis, and ovarian cancer is a representative example. In the present study, we measured the serum ATX antigen levels in patients with ovarian cancer and evaluated the usefulness of this parameter for clinical laboratory testing. The serum ATX antigen levels were not increased in ovarian cancer patients as compared with the levels in healthy subjects, and the serum ATX may not be useful as a biomarker for ovarian cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
